Detailed analysis of the “Usher Syndrome-Pipeline Review, H2 2016” helps to understand the various types of such products that are currently in use, along with the variants that would gain prominence in the future.
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Usher Syndrome – Pipeline Review, H2 2016, provides an overview of the Usher Syndrome (Genetic Disorders) pipeline landscape.
Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration, prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids and Vitamin A supplementation.
Key Companies Mentioned:
Amgen Inc, Editas Medicine Inc, ProQR Therapeutics NV and Sanofi.
Place a direct purchase order on this report at http://www.orbisresearch.com/contacts/discount/172620 . AND if you have enquire before buying this report visit at http://www.orbisresearch.com/contacts/enquiry-before-buying/172620 .
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Usher Syndrome – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Usher Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Usher Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Usher Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Discovery stages are 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Usher Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Browse the full report @ http://www.orbisresearch.com/reports/index/usher-syndrome-pipeline-review-h2-2016 .
List of Tables
Number of Products under Development for Usher Syndrome, H2 2016 7
Number of Products under Development for Usher Syndrome – Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Usher Syndrome – Pipeline by Amgen Inc, H2 2016 15
Usher Syndrome – Pipeline by Editas Medicine Inc, H2 2016 16
Usher Syndrome – Pipeline by ProQR Therapeutics NV, H2 2016 17
Usher Syndrome – Pipeline by Sanofi, H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Usher Syndrome – Dormant Projects, H2 2016 36… Continued
Request a sample for this report @ http://www.orbisresearch.com/contacts/request-sample/172620 .
– The pipeline guide provides a snapshot of the global therapeutic landscape of Usher Syndrome (Genetic Disorders).
– The pipeline guide reviews pipeline therapeutics for Usher Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Usher Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Usher Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Usher Syndrome (Genetic Disorders)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Usher Syndrome (Genetic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Usher Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: email@example.com
Follow Us on Linkedin: https://www.linkedin.com/company/orbis-research